Search

Your search keyword '"MORISCO, FILOMENA"' showing total 984 results
Start Over Author "MORISCO, FILOMENA"
984 results on '"MORISCO, FILOMENA"'

201. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon

Author

Petta, S., Cabibbo, G., Barbara, M., Attardo, S., Bucci, L., Farinati, F., Giannini, E. G., Tovoli, F., Ciccarese, F., Rapaccini, Gian Ludovico, Di Marco, M., Caturelli, E., Zoli, M., Borzio, F., Sacco, R., Virdone, R., Marra, F., Felder, M., Morisco, F., Benvegnù, L., Gasbarrini, Antonio, Svegliati-Baroni, G., Foschi, F. G., Olivani, A., Masotto, A., Nardone, G., Colecchia, A., Persico, M., Boccaccio, V., Craxì, A., Bruno, S., Trevisani, F., Cammà, C, Biselli, Maurizio, Caraceni, Paolo, Cucchetti, Alessandro, Domenicali, Marco, Piscaglia, Fabio, Gramenzi, Annagiulia, Granito, Alessandro, Magalotti, Donatella, Serra, Carla, Negrini, Giulia, Napoli, L., Napoli, Lucia, Salvatore, Veronica, Benevento, Francesca, Gazzola, Alessia, Murer, Francesca, Pozzan, Caterina, Vanin, Veronica, Moscatelli, Alessandro, Pellegatta, Gaia, Picciotto, Antonino, Savarino, Vincenzo, Delpoggio, Paolo, Olmi, Stefano, De Matthaeis, Nicoletta, Balsamo, Claudia, Vavassori, Elena, Roselli, Paola, Dell’Isola, Serena, Ialungo, Anna Maria, Rastrelli, Elena, Rini, Francesca, Costantino, Andrea, Affronti, Andrea, Affronti, Marco, Mascari, Marta, Mega, Andrea, Pompili, Maurizio, Rinninella, Emanuele, Mismas, Valeria, Dall’Aglio, Anna Chiara, Feletti, Valentina, Lanzi, Arianna, Cappa, Federica Mirici, Neri, Elga, Stefanini, Giuseppe Francesco, Tamberi, Stefano, Biasini, Elisabetta, Missale, Gabriele, Guarino, Maria, Ortolani, Alessio, Chiaramonte, Maria, Marchetti, Fabiana, Valerio, Matteo, Aburas, Sami, Inghilesi, Andrea L., Cappelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Coccoli, Piero, Zamparelli, Marco Sanduzzi, Petta, Salvatore, Cabibbo, Giuseppe, Barbara, Marco, Attardo, Simona, Bucci, Laura, Farinati, Fabio, Giannini, Edoardo G., Tovoli, Francesco, Ciccarese, Francesca, Rapaccini, Gian Lodovico, Dimarco, Maria, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Sacco, Rodolfo, Virdone, Roberto, Marra, Fabio, Felder, Martina, Morisco, Filomena, Benvegnù, Luisa, Svegliati-Baroni, Gianluca, Foschi, Francesco Giuseppe, Olivani, Andrea, Masotto, Alberto, Nardone, Gerardo, Colecchia, Antonio, Persico, Marcello, Boccaccio, Vincenzo, Craxì, Antonio, Bruno, Savino, Trevisani, Franco, Cammà, Calogero, Petta, S, Cabibbo, G, Barbara, M, Attardo, S, Bucci, L, Farinati, F, Giannini, E. G, Tovoli, F, Ciccarese, F, Rapaccini, G. L, Di Marco, M, Caturelli, E, Zoli, M, Borzio, F, Sacco, R, Virdone, R, Marra, F, Felder, M, Morisco, Filomena, Benvegnù, L, Gasbarrini, A, Svegliati Baroni, G, Foschi, F. G, Olivani, A, Masotto, A, Nardone, GERARDO ANTONIO PIO, Colecchia, A, Persico, M, Boccaccio, V, Craxì, A, Bruno, S, Trevisani, F, Cammà, C., DIPARTIMENTO DI MEDICINA SPECIALISTICA, DIAGNOSTICA E SPERIMENTALE, DIPARTIMENTO DI SCIENZE MEDICHE E CHIRURGICHE, Facolta' di MEDICINA e CHIRURGIA, Da definire, AREA MIN. 06 - Scienze mediche, Petta, S., Cabibbo, G., Barbara, M., Attardo, S., Bucci, L., Farinati, F., Giannini, E., Tovoli, F., Ciccarese, F., Rapaccini, G., Di Marco, M., Caturelli, E., Zoli, M., Borzio, F., Sacco, R., Virdone, R., Marra, F., Felder, M., Morisco, F., Benvegnã¹, L., Gasbarrini, A., Svegliati-Baroni, G., Foschi, F., Olivani, A., Masotto, A., Nardone, G., Colecchia, A., Persico, M., Boccaccio, V., Craxi, A., Bruno, S., Trevisani, F., Camma', C., Biselli, M., Caraceni, P., Cucchetti, A., Domenicali, M., Piscaglia, F., Gramenzi, A., Granito, A., Magalotti, D., Serra, C., Negrini, G., Napoli, L., Salvatore, V., Benevento, F., Gazzola, A., Murer, F., Pozzan, C., Vanin, V., Moscatelli, A., Pellegatta, G., Picciotto, A., Savarino, V., Delpoggio, P., Olmi, S., Dematthaeis, N., Balsamo, C., Vavassori, E., Roselli, P., Dell’Isola, S., Ialungo, A., Rastrelli, E., Rini, F., Costantino, A., Affronti, A., Affronti, M., Mascari, M., Mega, A., Pompili, M., Rinninella, E., Mismas, V., Dall’Aglio, A., Feletti, V., Lanzi, A., Cappa, F., Neri, E., Stefanini, G., Tamberi, S., Biasini, E., Missale, G., Guarino, M., Ortolani, A., Chiaramonte, M., Marchetti, F., Valerio, M., Aburas, S., Inghilesi, A., Cappelli, A., Golfieri, R., Mosconi, C., Renzulli, M., Coccoli, P., Zamparelli, M., Giannini, E.G., Rapaccini, G.L., Benvegnù, L., Foschi, F.G., Craxì, A., Cammà, C, the Italian Liver Cancer (ITALICA) Group [, Maurizio Biselli, Paolo Caraceni, Alessandro Cucchetti, Marco Domenicali, Fabio Piscaglia, Annagiulia Gramenzi, Alessandro Granito, Donatella Magalotti, Carla Serra, Giulia Negrini, Lucia Napoli, Veronica Salvatore, Francesca Benevento, ], Giannini, E. G., Rapaccini, G. L., Benvegnu, L., Foschi, F. G., Camma, C., Dell'Isola, S., Ialungo, A. M., Dall'Aglio, A. C., Cappa, F. M., Stefanini, G. F., Inghilesi, A. L., and Zamparelli, M. S.

Subjects
Liver Cirrhosis, Male, Cirrhosis, Databases, Factual, Gastroenterology, HCV-infected cirrhotic patients, hepatocellular carcinoma, HCC, sustained viral eradication, SVR, interferon, 0302 clinical medicine, Retrospective Studie, Pharmacology (medical), Prospective Studies, Prospective cohort study, Aged, 80 and over, Liver Neoplasms, virus diseases, Hepatitis C, Middle Aged, Liver Neoplasm, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, Catheter Ablation, Interferon, 030211 gastroenterology & hepatology, Female, Liver cancer, Human, Adult, medicine.medical_specialty, Carcinoma, Hepatocellular, Liver Cirrhosi, Antiviral Agents, Follow-Up Studie, 03 medical and health sciences, Internal medicine, medicine, Carcinoma, Early Hepatocellular Carcinoma, Humans, Aged, Retrospective Studies, Antiviral Agent, Hepatology, business.industry, Settore MED/09 - MEDICINA INTERNA, Retrospective cohort study, medicine.disease, digestive system diseases, Surgery, Prospective Studie, Interferons, Neoplasm Recurrence, Local, business, Follow-Up Studies
Abstract

none 48 no Background: In HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma (HCC), the time to HCC recurrence and the effects of sustained viral eradication (SVR) by interferon (IFN)-based or IFN-free regimens on HCC recurrence remain unclear. Aim: To perform an indirect comparison of time to recurrence (TTR) in patients with successfully treated early HCC and active HCV infection with those of patients with SVR by IFN-based and by IFN-free regimens. Methods: We evaluated 443 patients with HCV-related cirrhosis and Barcelona Clinic Liver Cancer Stage A/0 HCC who had a complete radiological response after curative resection or ablation. Active HCV infection was present in 328, selected from the Italian Liver Cancer group cohort; 58 patients had SVR achieved by IFN-free regimens after HCC cure, and 57 patients had SVR achieved by IFN-based regimens after HCC cure. Individual data of patients in the last two groups were extracted from available publications. Results: TTR by Kaplan–Meier curve was significantly lower in patients with active HCV infection compared with those with SVR both by IFN-free (P = 0.02) and by IFN-based (P < 0.001) treatments. TTR was similar in patients with SVR by IFN-free or by IFN-based (P = 0.49) strategies. Conclusion: In HCV-infected, successfully treated patients with early HCC, SVR obtained by IFN-based or IFN-free regimens significantly reduce tumour recurrence without differences related to the anti-viral strategy used. Petta, S.; Cabibbo, G.; Barbara, M.; Attardo, S.; Bucci, L.; Farinati, F.; Giannini, E.G.; Tovoli, F.; Ciccarese, F.; Rapaccini, G.L.; Di Marco, M.; Caturelli, E.; Zoli, M.; Borzio, F.; Sacco, R.; Virdone, R.; Marra, F.; Felder, M.; Morisco, F.; Benvegnù, L.; Gasbarrini, A.; Svegliati-Baroni, G.; Foschi, F.G.; Olivani, A.; Masotto, A.; Nardone, G.; Colecchia, A.; Persico, M.; Boccaccio, V.; Craxì, A.; Bruno, S.; Trevisani, F.; Cammà, C; the Italian Liver Cancer (ITALICA) Group [ ; Maurizio Biselli; Paolo Caraceni; Alessandro Cucchetti; Marco Domenicali; Fabio Piscaglia; Annagiulia Gramenzi; Alessandro Granito; Donatella Magalotti; Carla Serra; Giulia Negrini; Lucia Napoli; Veronica Salvatore; Francesca Benevento;] Petta, S.; Cabibbo, G.; Barbara, M.; Attardo, S.; Bucci, L.; Farinati, F.; Giannini, E.G.; Tovoli, F.; Ciccarese, F.; Rapaccini, G.L.; Di Marco, M.; Caturelli, E.; Zoli, M.; Borzio, F.; Sacco, R.; Virdone, R.; Marra, F.; Felder, M.; Morisco, F.; Benvegnù, L.; Gasbarrini, A.; Svegliati-Baroni, G.; Foschi, F.G.; Olivani, A.; Masotto, A.; Nardone, G.; Colecchia, A.; Persico, M.; Boccaccio, V.; Craxì, A.; Bruno, S.; Trevisani, F.; Cammà, C; the Italian Liver Cancer (ITALICA) Group [ ; Maurizio Biselli; Paolo Caraceni; Alessandro Cucchetti; Marco Domenicali; Fabio Piscaglia; Annagiulia Gramenzi; Alessandro Granito; Donatella Magalotti; Carla Serra; Giulia Negrini; Lucia Napoli; Veronica Salvatore; Francesca Benevento;]

Published
2017

202. Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects

Author

Loguercio, Carmela, De Girolamo, Vincenzo, de Sio, Ilario, Tuccillo, Concetta, Ascione, Antonio, Baldi, Feliciano, Budillon, Gabriele, Cimino, Lucia, Di Carlo, Antonio, Pia Di Marino, Maria, Morisco, Filomena, Picciotto, Francesco, Terracciano, Luigi, Vecchione, Raffaella, Verde, Veronica, and Del Vecchio Blanco, Camillo

Published
2001
Full Text
View/download PDF

203. Metabolic‐associated fatty liver disease (MAFLD) in coeliac disease.

Author

Rispo, Antonio, Imperatore, Nicola, Guarino, Maria, Tortora, Raffaella, Alisi, Anna, Cossiga, Valentina, Testa, Anna, Ricciolino, Simona, Fiorentino, Andrea, and Morisco, Filomena

Subjects
FATTY liver, CELIAC disease, GLUTEN-free diet
Abstract

Background and aims: Coeliac disease (CD) is considered a high‐risk condition for developing non‐alcoholic fatty liver disease (NAFLD) and other related metabolic disorders, particularly after commencing gluten‐free diet (GFD). Recently, a new concept of metabolic‐associated fatty liver disease (MAFLD) has been proposed to overcome the limitations of NAFLD definition. This study aimed at exploring the prevalence of NAFLD and MAFLD in CD patients at the time of CD diagnosis and after 2 years of GFD. Furthermore, we evaluated the role of PNPLA3 rs738409 in the development of NAFLD and MAFLD in the same population. Methods: We retrospectively enrolled all newly diagnosed CD patients who underwent clinical, laboratory and ultrasonography investigations both at diagnosis and after 2 years of follow‐up. Moreover, a PNPLA3 rs738409 genotyping assay was performed. Results: Of 221 newly diagnosed CD patients, 65 (29.4%) presented NAFLD at CD diagnosis, while 32 (14.5%) met the criteria for MAFLD (k = 0.57). There were no significant differences between NAFLD and MAFLD, except for the higher rate of insulin resistance (IR) of MAFLD patients (75% vs 33.8%, P <.001). At 2 years of follow‐up, 46.6% of patients developed NAFLD while 32.6% had MAFLD (k = 0.71). MAFLD subjects had higher transaminases (P =.03), LDL‐cholesterol (P =.04), BMI and waist circumference and higher IR than NAFLD patients. MAFLD patients showed higher non‐invasive liver fibrosis scores than NAFLD subjects (APRI = 1.43 ± 0.56 vs 0.91 ± 0.62, P <.001; NFS=−1.72 ± 1.31 vs −2.18 ± 1.41, P =.03; FIB‐4 = 1.27 ± 0.77 vs 1.04 ± 0.74, P =.04). About PNPLA3 polymorphisms, at 2 years follow‐up, NAFLD subjects presented a higher rate of heterozygosis (40.8%) and homozygosis (18.4%) polymorphisms than non‐NAFLD (26.3% and 7.6%, respectively, P =.03 and 0.02), while no correlation between PNPLA3 polymorphisms and MAFLD was seen. Conclusions: The new MAFLD definition better reflects the metabolic alterations following GFD in CD population. This new classification could be able to identify patients at higher risk of worse metabolic outcome, who need a close multidisciplinary approach for their multisystemic disease. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

204. Chronic hepatitis B virus infection in Italy during the twenty-first century: an updated survey in 2019.

Author

Stroffolini, Tommaso, Ciancio, Alessia, Furlan, Caterina, Vinci, Maria, Niro, Grazia Anna, Russello, Maurizio, Colloredo, Guido, Morisco, Filomena, Coppola, Nicola, Babudieri, Sergio, Ferrigno, Luigina, Sagnelli, Caterina, Sagnelli, Evangelista, Collaborating group, Verzon, Giulia, Latanza, Arianna, Picciotto, Viviana, Fontana, Rosanna, Benigno, Rosa Grazia, and Pontillo, Giuseppina

Subjects
HEPATITIS B virus, VIRUS diseases, TWENTY-first century, MULTIPLE regression analysis, LOGISTIC regression analysis, DRUG carriers
Abstract

The aim of this study is to provide updates on the characteristics of chronic HBsAg carriers in Italy before the advent of new drugs eliminating or functionally inactivating the genome HBV reservoirs. HBV endemicity has greatly decreased in Italy over the past decades. A not negligible number of chronic HBsAg carriers are still alive in the country. Chronic HBsAg carriers consecutively referring to 9 units in Italy were prospectively enrolled for a 6-month period in 2019. Multiple logistic regression analysis was performed to identify independent predictors of treatment. A total of 894 cases was recruited (sex ratio 1.6; mean age 53.7 ± 13.5 years). The proportion of subjects born abroad was 19.0%; only 1% of cases reported current heavy alcohol intake (> 4 units/day). Chronic HBV infection, chronic HBV hepatitis, and subjects with liver cirrhosis and/or HCC represented 24.8%, 55%, and 19.3% of cases, respectively. After exclusion of the 222 subjects with chronic HBV infection, the proportion of subjects under therapy was as high as 89.3%. A more severe liver disease (OR 2.52; 95% CI = 1.25–5.14) resulted an independent predictor of the likelihood of treatment; male sex was marginally associated (OR 1.67; 95% CI = 1.02–2.76) to the chance of treatment. People born abroad had same chance than Italians native to be treated (OR 2.12; 95% CI = 0.9–4.97). The high proportion of subjects under treatment and the absence of gender and ethnic barrier against treatment sound good news. These updated figures may represent reference data for evaluating the potential impact of forthcoming new therapy against HBV-related disease. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

205. The changing scenario of hepatocellular carcinoma in Italy: an update.

Author

Garuti, Francesca, Neri, Andrea, Avanzato, Francesca, Gramenzi, Annagiulia, Rampoldi, Davide, Rucci, Paola, Farinati, Fabio, Giannini, Edoardo G., Piscaglia, Fabio, Rapaccini, Gian Ludovico, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Sacco, Rodolfo, Cabibbo, Giuseppe, Marra, Fabio, Mega, Andrea, Morisco, Filomena, Gasbarrini, Antonio, and Svegliati‐Baroni, Gianluca

Subjects
LIVER cancer, LIVER analysis, CATHETER ablation, LIVER transplantation
Abstract

Background and aims: Epidemiology of hepatocellular carcinoma (HCC) is changing in most areas of the world. This study aimed at updating the changing scenario of aetiology, clinical presentation, management and prognosis of HCC in Italy during the last 15 years. Methods: Retrospective analysis of the Italian Liver Cancer (ITA.LI.CA) database included 6034 HCC patients managed in 23 centres from 2004 to 2018. Patients were divided into three groups according to the date of cancer diagnosis (2004‐2008, 2009‐2013 and 2014‐2018). Results: The main results were: (i) a progressive patient ageing; (ii) a progressive increase of non‐viral cases and, particularly, of 'metabolic' and 'metabolic + alcohol' HCCs; (iii) a slightly decline of cases diagnosed under surveillance, but with an incremental use of the semiannual schedule; (iv) a favourable cancer stage migration; (v) an increased use of radiofrequency ablation to the detriment of percutaneous ethanol injection; (vi) improved outcomes of ablative and transarterial treatments; (vii) an improved overall survival (adjusted for the lead time in surveyed patients) in the last calendar period, particularly in viral patients; (viii) a large gap between the number of potential candidates (according to oncologic criteria and age) to liver transplant and that of transplanted patients. Conclusions: During the last 15 years several aspects of HCC scenario have changed, as well as its management. The improvement in patient survival observed in the last period was likely because of a larger use of thermal ablation with respect to the less effective alcohol injection and to an improved management of intermediate stage patients. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

206. Corrigendum to 'Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV' [J Hepatol 68 (2018) 33–41](S0168827817322596)(10.1016/j.jhep.2017.08.019)

Author

Karampatou, Aimilia, Han, Xue, Kondili, Loreta A., Taliani, Gloria, Ciancio, Alessia, Morisco, Filomena, Critelli, Rosina Maria, Baraldi, Enrica, Bernabucci, Veronica, Troshina, Giulia, Guarino, Maria, Tagliavini, Simonetta, D'Ambrosio, Federica, Bristot, Laura, Turco, Laura, Rosato, Stefano, Vella, Stefano, Trenti, Tommaso, Neri, Isabella, La Marca, Antonio, Manthena, Shivaji, Goldstein, Andrea S., Bruno, Savino, Bao, Yanjun, Gonzalez, Yuri Sanchez, and Villa, Erica

Subjects
Hepatology
Published
2018

207. Correction to: Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma (The American Journal of Gastroenterology, (2016), 111, 1, (70-77), 10.1038/ajg.2015.389)

Author

Giannini, Edoardo G., Moscatelli, Alessandro, Pellegatta, Gaia, Vitale, Alessandro, Farinati, Fabio, Ciccarese, Francesca, Piscaglia, Fabio, Rapaccini, Gian Lodovico, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Cabibbo, Giuseppe, Felder, Martina, Sacco, Rodolfo, Morisco, Filomena, Missale, Gabriele, Foschi, Francesco Giuseppe, Gasbarrini, Antonio, Baroni, Gianluca Svegliati, Virdone, Roberto, Masotto, Alberto, and Trevisani, Franco

Subjects
Hepatology, Gastroenterology
Published
2018

208. Review: gut microbiota and functional diseases of the gastrointestinal tract

Author

IMPERATORE, NICOLA, MORISCO, FILOMENA, CAPORASO, NICOLA, Tortora, Raffaella, Imperatore, Nicola, Tortora, Raffaella, Morisco, Filomena, and Caporaso, Nicola

Abstract

Functional gastrointestinal disorders (FGIDs) are a common group of chronic gastrointestinal (GI) diseases defined by symptom-based diagnostic criteria, which consider chronic or recurrent symptoms of the GI tract in the absence of other organic or biochemical reasons. Recent evidences have been highlighted the role of gut microbiota in the pathophysiology of the FGIDs.

Published
2016

209. Application of the Intermediate-Stage Subclassification to Patients With Untreated Hepatocellular Carcinoma

Author

Giannini, Edoardo G, Moscatelli, Alessandro, Pellegatta, Gaia, Vitale, Alessandro, Farinati, Fabio, Ciccarese, Francesca, Piscaglia, Fabio, Rapaccini, Gian Lodovico, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Cabibbo, Giuseppe, Felder, Martina, Sacco, Rodolfo, Morisco, Filomena, Missale, Gabriele, Foschi, Francesco Giuseppe, Gasbarrini, Antonio, Baroni, Gianluca Svegliati, Virdone, Roberto, Masotto, Alberto, Trevisani, Franco, Bolondi, Luigi, Biselli, Maurizio, Caraceni, Paolo, Cucchetti, Alessandro, Domenicali, Marco, Gramenzi, Annagiulia, Magalotti, Donatella, Pecorelli, Anna, Serra, Carla, Venerandi, Laura, Gazzola, Alessia, Murer, Francesca, Pozzan, Caterina, Vanin, Veronica, Del Poggio, Paolo, Olmi, Stefano, Balsamo, Claudia, Vavassori, Elena, Benvegnu', Luisa, Capelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Bosco, Giulia, Roselli, Paola, Dell'Isola, Serena, Maria Ialungo, Anna, Rastrelli, Elena, Picciotto, Antonino, Savarino, Vincenzo, Mega, Andrea, Rinninella, Emanuele, Mismas, Valeria, Lanzi, Arianna, Cappa, Federica Mirici, Musetto, Alessandro, Neri, Elga, Stefanini, Giuseppe Francesco, Suzzi, Alessandra, Tamberi, Stefano, Triossi, Omero, Chiaramonte, Maria, Marchetti, Fabiana, Valerio, Matteo, Giannini, Edoardo G, Moscatelli, Alessandro, Pellegatta, Gaia, Vitale, Alessandro, Farinati, Fabio, Ciccarese, Francesca, Piscaglia, Fabio, Rapaccini, Gian Lodovico, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Cabibbo, Giuseppe, Felder, Martina, Sacco, Rodolfo, Morisco, Filomena, Missale, Gabriele, Foschi, Francesco Giuseppe, Gasbarrini, Antonio, Baroni, Gianluca Svegliati, Virdone, Roberto, Masotto, Alberto, Trevisani, Franco, Bolondi, Luigi, Biselli, Maurizio, Caraceni, Paolo, Cucchetti, Alessandro, Domenicali, Marco, Gramenzi, Annagiulia, Magalotti, Donatella, Pecorelli, Anna, Serra, Carla, Venerandi, Laura, Gazzola, Alessia, Murer, Francesca, Pozzan, Caterina, Vanin, Veronica, Del Poggio, Paolo, Olmi, Stefano, Balsamo, Claudia, Vavassori, Elena, Benvegnù, Luisa, Capelli, Alberta, Golfieri, Rita, Mosconi, Cristina, Renzulli, Matteo, Bosco, Giulia, Roselli, Paola, Dell'Isola, Serena, Maria Ialungo, Anna, Rastrelli, Elena, Picciotto, Antonino, Savarino, Vincenzo, Mega, Andrea, Rinninella, Emanuele, Mismas, Valeria, Lanzi, Arianna, Cappa, Federica Mirici, Musetto, Alessandro, Neri, Elga, Stefanini, Giuseppe Francesco, Suzzi, Alessandra, Tamberi, Stefano, Triossi, Omero, Chiaramonte, Maria, Marchetti, Fabiana, and Valerio, Matteo

Subjects
Adult, Male, medicine.medical_specialty, Carcinoma, Hepatocellular, Prognosi, Aged, Aged, 80 and over, Female, Humans, Liver Neoplasms, Middle Aged, Neoplasm Staging, Prognosis, Prospective Studies, Young Adult, Gastroenterology, Intermediate stage, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Carcinoma, 80 and over, Prospective cohort study, Hepatology, business.industry, Medicine (all), Settore MED/09 - MEDICINA INTERNA, Hepatocellular, medicine.disease, Prospective Studie, Liver Neoplasm, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, 030211 gastroenterology & hepatology, Neoplasm staging, Liver cancer, business, Human
Abstract

OBJECTIVES:The Barcelona Clinic Liver Cancer (BCLC) intermediate stage (BCLC B) includes a heterogeneous population of patients with hepatocellular carcinoma (HCC). Recently, in order to facilitate treatment decisions, a panel of experts proposed to subclassify BCLC B patients. In this study, we aimed to assess the prognostic capability of the BCLC B stage reclassification in a large cohort of patients with untreated HCC managed by the Italian Liver Cancer Group.METHODS:We assessed the prognosis of 269 untreated HCC patients observed in the period 1987-2012 who were reclassified according to the proposed subclassification of the BCLC B stage from stage B1 to stage B4. We evaluated and compared the survival of the various substages.RESULTS:Median survival progressively decreased from stage B1 (n=65, 24.2%: 25 months) through stages B2 (n=105, 39.0%: 16 months) and B3 (n=22, 8.2%: 9 months), to stage B4 (n=77, 28.6%: 5 months; P

Published
2016

210. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study

Author

Piscaglia, Fabio, Svegliati Baroni, Gianluca, Barchetti, Andrea, Pecorelli, Anna, Marinelli, Sara, Tiribelli, Claudio, Bellentani, Stefano, Bernardi M, Biselli M, Bernardi M, Biselli M, Caraceni P, Domenicali M, Garuti F, Gramenzi A, Lenzi B, Magalotti D, Cescon M, Ravaioli M, Del Poggio P, Olmi S, Rapaccini GL, Balsamo C, Di Nolfo MA, Vavassori E, Alberti A, Benvegnù L, Gatta A, Giacomin A, Vanin V, Pozzan C, Maddalo G, Giampalma E, Cappelli A, Golfieri R, Mosconi C, Renzulli M, Roselli P, Dell'Isola S, Ialungo AM, Risso D, Marenco S, Sammito G, Bruzzone L, Bosco G, Grieco A, Pompili M, Rinninella E, Siciliano M, Chiaramonte M, Guarino M, Cammà C, Maida M, Costantino A, Barcellona MR, Schiadà L, Gemini S, Lanzi A, Stefanini GF, Dall'Aglio AC, Cappa FM, Suzzi A, Mussetto A, Treossi O, Missale G, Porro E, Mismas V, Vivaldi C, Bolondi L, Zoli M, Granito A, Malagotti D, Tovoli F, Trevisani F, Venerandi L, Brandi G, Cucchetti A, Bugianesi E, Vanni E, Mezzabotta L, Cabibbo G, Petta S, Fracanzani A, Fargion S, Marra F, Fani B, Biasini E, Sacco R, CAPORASO, NICOLA, Colombo M, D'Ambrosio R, Crocè LS, Patti R, Giannini EG, Loria P, Lonardo A, Baldelli E, Miele L, Farinati F, Borzio M, Dionigi E, Soardo G, Caturelli E, Ciccarese F, Virdone R, Affronti A, Foschi FG, Borzio F., MORISCO, FILOMENA, Piscaglia, Fabio, Svegliati Baroni, Gianluca, Barchetti, Andrea, Pecorelli, Anna, Marinelli, Sara, Tiribelli, Claudio, Bellentani, Stefano, Bernardi M, Biselli M, Bernardi, M, Biselli, M, Caraceni, P, Domenicali, M, Garuti, F, Gramenzi, A, Lenzi, B, Magalotti, D, Cescon, M, Ravaioli, M, Del Poggio, P, Olmi, S, Rapaccini, Gl, Balsamo, C, Di Nolfo, Ma, Vavassori, E, Alberti, A, Benvegnù, L, Gatta, A, Giacomin, A, Vanin, V, Pozzan, C, Maddalo, G, Giampalma, E, Cappelli, A, Golfieri, R, Mosconi, C, Renzulli, M, Roselli, P, Dell'Isola, S, Ialungo, Am, Risso, D, Marenco, S, Sammito, G, Bruzzone, L, Bosco, G, Grieco, A, Pompili, M, Rinninella, E, Siciliano, M, Chiaramonte, M, Guarino, M, Cammà, C, Maida, M, Costantino, A, Barcellona, Mr, Schiadà, L, Gemini, S, Lanzi, A, Stefanini, Gf, Dall'Aglio, Ac, Cappa, Fm, Suzzi, A, Mussetto, A, Treossi, O, Missale, G, Porro, E, Mismas, V, Vivaldi, C, Bolondi, L, Zoli, M, Granito, A, Malagotti, D, Tovoli, F, Trevisani, F, Venerandi, L, Brandi, G, Cucchetti, A, Bugianesi, E, Vanni, E, Mezzabotta, L, Cabibbo, G, Petta, S, Fracanzani, A, Fargion, S, Marra, F, Fani, B, Biasini, E, Sacco, R, Morisco, Filomena, Caporaso, Nicola, Colombo, M, D'Ambrosio, R, Crocè, L, Patti, R, Giannini, Eg, Loria, P, Lonardo, A, Baldelli, E, Miele, L, Farinati, F, Borzio, M, Dionigi, E, Soardo, G, Caturelli, E, Ciccarese, F, Virdone, R, Affronti, A, Foschi, Fg, Borzio, F., Fabio Piscagliaxxx, Gianluca Svegliati-Baroni, Andrea Barchetti, Anna Pecorellixxx, Sara Marinellixxx, Claudio Tiribelli, and, Stefano Bellentani, on behalf of the HCC-NAFLD Italian Study Group [, Mauro Bernardi, Maurizio Biselli, Paolo Caraceni, Marco Domenicali, Francesca Garuti, Annagiulia Gramenzi, Barbara Lenzi, Donatella Magalotti, Matteo Cescon, Matteo Ravaioli, Emanuela Giampalma, Rita Golfieri, Cristina Mosconi, Luigi Bolondi, Marco Zoli, Alessandro Granito, Francesco Tovoli, Franco Trevisani, Laura Venerandi, Giovanni Brandi, Alessandro Cucchetti, ], DIPARTIMENTO DI MEDICINA SPECIALISTICA, DIAGNOSTICA E SPERIMENTALE, DIPARTIMENTO DI SCIENZE MEDICHE E CHIRURGICHE, Facolta' di MEDICINA e CHIRURGIA, AREA MIN. 06 - Scienze mediche, Da definire, Croce', Saveria, and HCC NAFLD Italian Study, Group

Subjects
Male, Cirrhosis, Survival, Chronic liver disease, Gastroenterology, 0302 clinical medicine, Non-alcoholic Fatty Liver Disease, Nonalcoholic fatty liver disease, 80 and over, Prospective Studies, Chronic, Prospective cohort study, Aged, 80 and over, Medicine (all), Liver Neoplasms, hepatocellular carcinoma, Middle Aged, Hepatitis C, Liver Neoplasm, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, Competing risk analysi, 030211 gastroenterology & hepatology, Female, Non Alcoholic SteatoHepatitis=NASH, Human, medicine.medical_specialty, Aged, Carcinoma, Hepatocellular, Hepatitis C, Chronic, Humans, Hepatology, Competing risk analysis, Milan criteria, 03 medical and health sciences, Internal medicine, medicine, Survival rate, business.industry, Settore MED/09 - MEDICINA INTERNA, Carcinoma, nutritional and metabolic diseases, Hepatocellular, medicine.disease, digestive system diseases, Nonalcoholic fatty liver disease, hepatocellular carcinoma, clinical patterns, business, clinical patterns
Abstract

none 31 no Nonalcoholic fatty liver disease (NAFLD) represents the hepatic manifestation of metabolic syndrome and may evolve into hepatocellular carcinoma (HCC). Only scanty clinical information is available on HCC in NAFLD. The aim of this multicenter observational prospective study was to assess the clinical features of patients with NAFLD-related HCC (NAFLD-HCC) and to compare them to those of hepatitis C virus (HCV)-related HCC. A total of 756 patients with either NAFLD (145) or HCV-related chronic liver disease (611) were enrolled in secondary care Italian centers. Survival was modeled according to clinical parameters, lead-time bias, and propensity analysis. Compared to HCV, HCC in NAFLD patients had a larger volume, showed more often an infiltrative pattern, and was detected outside specific surveillance. Cirrhosis was present in only about 50% of NAFLD-HCC patients, in contrast to the near totality of HCV-HCC. Regardless of tumor stage, survival was significantly shorter (P = 0.017) in patients with NAFLD-HCC, 25.5 months (95% confidence interval 21.9-29.1), than in those with HCV-HCC, 33.7 months (95% confidence interval 31.9-35.4). To eliminate possible confounders, a propensity score analysis was performed, which showed no more significant difference between the two groups. Additionally, analysis of patients within Milan criteria submitted to curative treatments did not show any difference in survival between NAFLD-HCC and HCV-HCC (respectively, 38.6 versus 41.0 months, P = nonsignificant) CONCLUSIONS: NAFLD-HCC is more often detected at a later tumor stage and could arise also in the absence of cirrhosis, but after patient matching, it has a similar survival rate compared to HCV infection; a future challenge will be to identify patients with NAFLD who require more stringent surveillance in order to offer the most timely and effective treatment. Fabio Piscagliaxxx; Gianluca Svegliati-Baroni; Andrea Barchetti; Anna Pecorellixxx; Sara Marinellixxx; Claudio Tiribelli; and; Stefano Bellentani; on behalf of the HCC-NAFLD Italian Study Group [;Mauro Bernardi; Maurizio Biselli; Paolo Caraceni; Marco Domenicali; Francesca Garuti; Annagiulia Gramenzi; Barbara Lenzi; Donatella Magalotti; Matteo Cescon; Matteo Ravaioli; Emanuela Giampalma; Rita Golfieri; Cristina Mosconi; Luigi Bolondi; Marco Zoli; Alessandro Granito; Francesco Tovoli; Franco Trevisani; Laura Venerandi; Giovanni Brandi; Alessandro Cucchetti;] Fabio Piscagliaxxx; Gianluca Svegliati-Baroni; Andrea Barchetti; Anna Pecorellixxx; Sara Marinellixxx; Claudio Tiribelli; and; Stefano Bellentani; on behalf of the HCC-NAFLD Italian Study Group [;Mauro Bernardi; Maurizio Biselli; Paolo Caraceni; Marco Domenicali; Francesca Garuti; Annagiulia Gramenzi; Barbara Lenzi; Donatella Magalotti; Matteo Cescon; Matteo Ravaioli; Emanuela Giampalma; Rita Golfieri; Cristina Mosconi; Luigi Bolondi; Marco Zoli; Alessandro Granito; Francesco Tovoli; Franco Trevisani; Laura Venerandi; Giovanni Brandi; Alessandro Cucchetti;]

Published
2016

211. Decaffeinated coffee consumption induces expression of tight junction proteins in high fat diet fed rats

Author

MAZZONE, GIOVANNA, Lembo, Vincenzo, D'ARGENIO, GIUSEPPE, VITAGLIONE, PAOLA, CAPORASO, NICOLA, MORISCO, FILOMENA, Rossi, A., Guarino, M., Mazzone, Giovanna, Lembo, Vincenzo, D'Argenio, Giuseppe, Vitaglione, Paola, Rossi, A., Guarino, M., Caporaso, Nicola, and Morisco, Filomena

Subjects
MICE, INFLAMMATION, LIVER-DISEASE, NONALCOHOLIC STEATOHEPATITIS, FRUCTOSE, OBESITY, GUT MICROBIOTA, PERMEABILITY, CIRRHOSIS, ENZYMES
Abstract

Background: Recent evidence indicates that gut microbiota plays a key role in the development of NAFLD through the gut-liver axis. An altered gut permeability induced by alterations of tight junction (TJ) proteins allows the passage of bacteria and substances leading to liver inflammation, hepatocyte damage and fibrosis. This study aims to evaluate the influence of decaffeinated coffee on gut permeability in a rat model of fat liver damage induced by a high fat diet (HFD). Methods: Twelve male Wistar rats were assigned to 3 groups. The first group received HFD for 5 months and drank water. The second group received HFD for 5 months and drank water added with 1.2mL decaffeinated coffee/day starting from the 4th month. The third group received standard diet (SD) and drank water. Protein and mRNA expression levels of Toll-Like Receptor-4 (TLR-4), Occludin and Zonula occludens-1 (ZO-1) were assessed in rat intestines. Results: A significant reduction of Occludin and ZO-1 was observed in HFD fed rats (0.97 +/- 0.05 vs 0.15 +/- 0.08 p. 0.01, and 0.97 +/- 0.05 vs 0.57 +/- 0.14 p

Published
2016

212. International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways

Author

Cordell, Heather J, Han, Younghun, Mells, George F, Li, Yafang, Hirschfield, Gideon M, Greene, Casey S, Xie, Gang, Juran, Brian D, Zhu, Dakai, Qian, David C, Floyd, James A. B, Morley, Katherine I, Prati, Daniele, Lleo, Ana, Cusi, Daniele, Gershwin, M. Eric, Anderson, Carl A, Lazaridis, Konstantinos N, Invernizzi, Pietro, Seldin, Michael F, Sandford, Richard N, Amos, Christopher I, Siminovitch, Katherine A., MORISCO, FILOMENA, Cordell, Heather J, Han, Younghun, Mells, George F, Li, Yafang, Hirschfield, Gideon M, Greene, Casey S, Xie, Gang, Juran, Brian D, Zhu, Dakai, Qian, David C, Floyd, James A. B, Morley, Katherine I, Prati, Daniele, Lleo, Ana, Cusi, Daniele, Gershwin, M. Eric, Anderson, Carl A, Lazaridis, Konstantinos N, Invernizzi, Pietro, Seldin, Michael F, Sandford, Richard N, Amos, Christopher I, Siminovitch, Katherine A., and Morisco, Filomena

Abstract

Primary biliary cirrhosis (PBC) is a classical autoimmune liver disease for which effective immunomodulatory therapy is lacking. Here we perform meta-analyses of discovery data sets from genome-wide association studies of European subjects (n=2,764 cases and 10,475 controls) followed by validation genotyping in an independent cohort (n=3,716 cases and 4,261 controls). We discover and validate six previously unknown risk loci for PBC (Pcombined

Published
2015
Full Text
View/download PDF

213. Coffee prevents fatty liver disease induced by a high-fat diet by modulating pathways of the gut–liver axis

Author

Vitaglione, Paola, primary, Mazzone, Giovanna, additional, Lembo, Vincenzo, additional, D'Argenio, Giuseppe, additional, Rossi, Antonella, additional, Guido, Maria, additional, Savoia, Marcella, additional, Salomone, Federico, additional, Mennella, Ilario, additional, De Filippis, Francesca, additional, Ercolini, Danilo, additional, Caporaso, Nicola, additional, and Morisco, Filomena, additional

Published
2019
Full Text
View/download PDF

214. Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort.

Author

Quaranta, Maria Giovanna, Ferrigno, Luigina, Monti, Monica, Filomia, Roberto, Biliotti, Elisa, Iannone, Andrea, Migliorino, Guglielmo, Coco, Barbara, Morisco, Filomena, Vinci, Maria, D'Ambrosio, Roberta, Chemello, Liliana, Massari, Marco, Ieluzzi, Donatella, Russo, Francesco Paolo, Blanc, Pierluigi, Verucchi, Gabriella, Puoti, Massimo, Rumi, Maria Grazia, and Barbaro, Francesco

Abstract

Background: Liver disease progression after Hepatitis C Virus (HCV) eradication following direct-acting antiviral (DAA) treatment in the real-life setting according to Human Immunodeficiency Virus (HIV) coinfection was evaluated. Methods: Patients consecutively enrolled in PITER between April 2014 and June 2019 and with at least 12-weeks follow-up following treatment were analysed. Cox regression analysis were used to evaluate HIV coinfection and factors independently associated with liver disease outcomes following viral eradication in DAA treated patients with pre-treatment liver cirrhosis. Results: 93 HIV/HCV coinfected and 1109 HCV monoinfected patients were evaluated during a median follow-up of 26.7 (range 6–44.6) and 24.6 (range 6.8–47.3) months, respectively. No difference in the cumulative HCC incidence and hepatic decompensation was observed between coinfected and monoinfected patients. Age (Hazard Ratio [HR] = 1.08; 95% CI 1.04–1.13), male sex (HR = 2.76; 95% CI 1.28–5.96), lower albumin levels (HR = 3.94; 95% CI 1.81–8.58), genotype 3 (HR = 5.05; 95% CI 1.75–14.57) and serum anti-HBc positivity (HR = 1.99, 95% CI 1.01–3.95) were independently associated with HCC incidence. Older age (HR = 1.03; 95% CI 1.00–1.07), male sex (HR = 2.13; 95% CI 1.06–4.26) and lower albumin levels (HR = 3.75; 95% CI 1.89–7.46) were independently associated with the appearance of a decompensating event after viral eradication. Conclusion: Different demographic, clinical and genotype distribution between HIV coinfected vs those monoinfected, was observed in a representative cohort of HCV infected patients in Italy. Once liver cirrhosis is established the disease progression is decreased, but still persists regardless of viral eradication in both coinfected and monoinfected patients. In patients with cirrhosis, HIV coinfection was not associated with a higher probability of liver complications, after viral eradication. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

215. Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis

Author

Guarino, Maria, primary, Viganò, Luca, additional, Ponziani, Francesca Romana, additional, Giannini, Edoardo Giovanni, additional, Lai, Quirino, additional, Morisco, Filomena, additional, Vitale, Alessandro, additional, Russo, Francesco Paolo, additional, Cillo, Umberto, additional, Burra, Patrizia, additional, Mescoli, Claudia, additional, Gambato, Martina, additional, Sessa, Anna, additional, Cabibbo, Giuseppe, additional, Viganò, Mauro, additional, Galati, Giovanni, additional, Villa, Erica, additional, Iavarone, Massimo, additional, Brancaccio, Giuseppina, additional, Rendina, Maria, additional, Lupo, Luigi G., additional, Losito, Francesco, additional, Fucilli, Fabio, additional, Persico, Marcello, additional, D’Ambrosio, Roberta, additional, Sangiovanni, Angelo, additional, Cucchetti, Alessandro, additional, Trevisani e Matteo Renzulli, Franco, additional, Miele, Luca, additional, Grieco, Antonio, additional, Lodovico Rapaccini, Gian, additional, Pompili, Maurizio, additional, Gasbarrini, Antonio, additional, Battista Levi Sandri, Giovanni, additional, Melandro, Fabio, additional, Rossi, Massimo, additional, Lenci, Ilaria, additional, Manzia, Tommaso Maria, additional, Tortora, Raffaella, additional, Di Costanzo, Giovan Giuseppe, additional, Sacco, Rodolfo, additional, Ghinolfi, Davide, additional, Rreka, Erion, additional, Carrai, Paola, additional, Simonetti, Natalia, additional, Sposito, Carlo, additional, Bhoori, Sherrie, additional, di Sandro, Stefano, additional, Foschi, Francesco Giuseppe, additional, Casadei Gardini, Andrea, additional, Nicolini, Daniele, additional, Mazzocato, Susanna, additional, Kostandini, Alba, additional, Violi, Paola, additional, Baccarani, Umberto, additional, Pravisani, Riccardo, additional, and Vincenzi, Valter, additional

Published
2018
Full Text
View/download PDF

217. PNPLA3 rs738409 Polymorphism Predicts Development and Severity of Hepatic Steatosis but Not Metabolic Syndrome in Celiac Disease

Author

Tortora, Raffaella, primary, Rispo, Antonio, additional, Alisi, Anna, additional, Imperatore, Nicola, additional, Crudele, Annalisa, additional, Ferretti, Francesca, additional, Nobili, Valerio, additional, Miele, Luca, additional, Gerbino, Nicolò, additional, Caporaso, Nicola, additional, and Morisco, Filomena, additional

Published
2018
Full Text
View/download PDF

219. Dietary supplementation of vitamin D prevents the development of western diet‐induced metabolic, hepatic and cardiovascular abnormalities in rats

Author

Mazzone, Giovanna, primary, Morisco, Carmine, additional, Lembo, Vincenzo, additional, D’Argenio, Giuseppe, additional, D’Armiento, Maria, additional, Rossi, Antonella, additional, Giudice, Carmine, additional, Trimarco, Bruno, additional, Caporaso, Nicola, additional, and Morisco, Filomena, additional

Published
2018
Full Text
View/download PDF

221. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial

Author

Caraceni, Paolo, primary, Riggio, Oliviero, additional, Angeli, Paolo, additional, Alessandria, Carlo, additional, Neri, Sergio, additional, Foschi, Francesco G, additional, Levantesi, Fabio, additional, Airoldi, Aldo, additional, Boccia, Sergio, additional, Svegliati-Baroni, Gianluca, additional, Fagiuoli, Stefano, additional, Romanelli, Roberto G, additional, Cozzolongo, Raffaele, additional, Di Marco, Vito, additional, Sangiovanni, Vincenzo, additional, Morisco, Filomena, additional, Toniutto, Pierluigi, additional, Tortora, Annalisa, additional, De Marco, Rosanna, additional, Angelico, Mario, additional, Cacciola, Irene, additional, Elia, Gianfranco, additional, Federico, Alessandro, additional, Massironi, Sara, additional, Guarisco, Riccardo, additional, Galioto, Alessandra, additional, Ballardini, Giorgio, additional, Rendina, Maria, additional, Nardelli, Silvia, additional, Piano, Salvatore, additional, Elia, Chiara, additional, Prestianni, Loredana, additional, Cappa, Federica Mirici, additional, Cesarini, Lucia, additional, Simone, Loredana, additional, Pasquale, Chiara, additional, Cavallin, Marta, additional, Andrealli, Alida, additional, Fidone, Federica, additional, Ruggeri, Matteo, additional, Roncadori, Andrea, additional, Baldassarre, Maurizio, additional, Tufoni, Manuel, additional, Zaccherini, Giacomo, additional, Bernardi, Mauro, additional, Domenicali, Marco, additional, Giannone, Ferdinando A, additional, Merli, Manuela, additional, Gioia, Stefania, additional, Fasolato, Silvano, additional, Sticca, Antonietta, additional, Campion, Daniela, additional, Risso, Alessandro, additional, Saracco, Giorgio M, additional, Maiorca, Daniela, additional, Rizzotto, Agostino, additional, Lanzi, Arianna, additional, Neri, Elga, additional, Visani, Anna, additional, Mastroianni, Antonio, additional, Alberti, Alberto B, additional, Mazzarelli, Chiara, additional, Vangeli, Marcello, additional, Marzioni, Marco, additional, Capretti, Francesca, additional, Kostandini, Alba, additional, Magini, Giulia, additional, Colpani, Maria, additional, Laffi, Giacomo, additional, Gabbani, Tommaso, additional, Marsico, Maria, additional, Zappimbulso, Marianna, additional, Petruzzi, Josè, additional, Calvaruso, Vincenza, additional, Parrella, Giovanni, additional, Caporaso, Nicola, additional, Auriemma, Francesco, additional, Guarino, Maria, additional, Pugliese, Fabio, additional, Gasbarrini, Antonio, additional, Leo, Pietro, additional, De Leonardis, Francesco, additional, Pecchioli, Alessandra, additional, Rossi, Piera, additional, Raimondo, Giovanni, additional, Negri, Elisa, additional, Dallio, Marcello, additional, Loguercio, Carmelina, additional, Conte, Dario, additional, Celli, Natascia, additional, Bringiotti, Roberto, additional, Castellaneta, Nicola M, additional, and Salerno, Francesco, additional

Published
2018
Full Text
View/download PDF

222. Corrigendum to “Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV” [J Hepatol 68 (2018) 33–41]

Author

Karampatou, Aimilia, primary, Han, Xue, additional, Kondili, Loreta A., additional, Taliani, Gloria, additional, Ciancio, Alessia, additional, Morisco, Filomena, additional, Critelli, Rosina Maria, additional, Baraldi, Enrica, additional, Bernabucci, Veronica, additional, Troshina, Giulia, additional, Guarino, Maria, additional, Tagliavini, Simonetta, additional, D'Ambrosio, Federica, additional, Bristot, Laura, additional, Turco, Laura, additional, Rosato, Stefano, additional, Vella, Stefano, additional, Trenti, Tommaso, additional, Neri, Isabella, additional, La Marca, Antonio, additional, Manthena, Shivaji, additional, Goldstein, Andrea S., additional, Bruno, Savino, additional, Bao, Yanjun, additional, Gonzalez, Yuri Sanchez, additional, and Villa, Erica, additional

Published
2018
Full Text
View/download PDF

223. Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?

Author

Di Maio, Velia Chiara, primary, Cento, Valeria, additional, Aragri, Marianna, additional, Paolucci, Stefania, additional, Pollicino, Teresa, additional, Coppola, Nicola, additional, Bruzzone, Bianca, additional, Ghisetti, Valeria, additional, Zazzi, Maurizio, additional, Brunetto, Maurizia, additional, Bertoli, Ada, additional, Barbaliscia, Silvia, additional, Galli, Silvia, additional, Gennari, William, additional, Baldanti, Fausto, additional, Raimondo, Giovanni, additional, Perno, Carlo Federico, additional, Ceccherini-Silberstein, Francesca, additional, Andreone, Pietro, additional, Andreoni, Massimo, additional, Angelico, Mario, additional, Babudieri, Sergio, additional, Barbarini, Giorgio, additional, Boccaccio, Vincenzo, additional, Boglione, Lucio, additional, Bolis, Matteo, additional, Bonora, Stefano, additional, Borghi, Vanni, additional, Brancaccio, Giuseppina, additional, Bruno, Savino, additional, Cacciatore, Pierluigi, additional, Calvaruso, Vincenza, additional, Caporaso, Nicola, additional, Ciaccio, Antonio, additional, Ciancio, Alessia, additional, Colombatto, Piero, additional, Cozzolongo, Raffaele, additional, Craxì, Antonio, additional, D'Ambrosio, Cecilia, additional, D'Ettorre, Gabriella, additional, De Luca, Andrea, additional, Di Biagio, Antonio, additional, Di Perri, Giovanni, additional, Francioso, Simona, additional, Gaeta, Giovanni Battista, additional, Giorgini, Alessia, additional, Grieco, Antonio, additional, Gubertini, Guido, additional, Gulminetti, Roberto, additional, Lambiase, Lara, additional, Lenci, Ilaria, additional, Lichtner, Miriam, additional, Maida, Ivana, additional, Marenco, Simona, additional, Marinaro, Letizia, additional, Maserati, Renato, additional, Masetti, Chiara, additional, Melis, Michela, additional, Meregalli, Elisa, additional, Micheli, Valeria, additional, Morisco, Filomena, additional, Niero, Fosca, additional, Nicolini, Laura Ambra, additional, Palitti, Valeria Pace, additional, Paoloni, Maurizio, additional, Parruti, Giustino, additional, Pasquazzi, Caterina, additional, Pellicelli, Adriano, additional, Polilli, Ennio, additional, Ponti, Maria Laura, additional, Puoti, Massimo, additional, Rendina, Maria, additional, Rizzardini, Giuliano, additional, Rossetti, Barbara, additional, Ruggiero, Tina, additional, Sangiovanni, Vincenzo, additional, Starace, Mario, additional, Sticchi, Laura, additional, Tarquini, Pierluigi, additional, Toniutto, Pierluigi, additional, and Vullo, Vincenzo, additional

Published
2018
Full Text
View/download PDF

224. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis

Author

Ascione, Antonio, De Luca, Massimo, Melazzini, Mario, Montilla, Simona, Trotta, Maria Paola, Petta, Salvatore, Puoti, Massimo, Sangiovanni, Vincenzo, Messina, Vincenzo, Bruno, Savino, Izzi, Antonio, Villa, Erica, Aghemo, Alessio, Zignego, Anna Linda, Orlandini, Alessandra, Fontanella, Luca, Gasbarrini, Antonio, Marzioni, Marco, Giannini, Edoardo G., Craxì, Antonio, Abbati, Giuseppe, Alberti, Alfredo, Andreone, Pietro, Andreoni, Massimo, Angeli, Paolo, Angelico, Mario, Angarano, Gioacchino, Angrisani, Debora, Antinori, Andrea, Antonini, Cinzia, Avancini, Ivo, Barone, Michele, Bruno, Raffaele, Benedetti, Antonio, Bernabucci, Veronica, Blanc, Pier, Boarini, Chiara, Boffa, Nicola, Boglione, Lucio, Borghi, Vanni, Borgia, Guglielmo, Brancaccio, Giuseppina, Brunetto, Maurizia, Cacciola, Irene, Calabrese, Paolo, Calvaruso, Vincenza, Campagnolo, Davide, Canovari, Benedetta, Caporaso, Nicola, Capra, Franco, Carolo, Giada, Cassola, Giovanni, Castelli, Francesco, Cauda, Roberto, Silberstein, Francesca Ceccherini, Cecere, Roberto, Chessa, Luchino, Chiodera, Alessandro, Chirianni, Antonio, Ciancio, Alessia, Cima, Serena, Coco, Barbara, Colombo, Massimo, Coppola, Nicola, Corti, Giampaolo, Cosco, Lucio, Corradori, Silvia, Cozzolongo, Raffaele, Cristaudo, Antonio, Danieli, Elena, Monforte, Antonella D’Arminio, Monache, Marco delle, Del Poggio, Paolo, de Luca, Andrea, Dentone, Chiara, Di Biagio, Antonio, Di Leo, Alfredo, Di Perri, Giovanni, Di Stefano, Marco, D’Offizi, Giampiero, Donato, Francesca, Durante, Emanuele, Erne, Elke, Fagiuoli, Stefano, Falasca, Katia, Federico, Alessandro, Felder, Martina, Ferrari, Carlo, Gaeta, Giovanni Battista, Ganga, Roberto, Gatti, Pietro, Giacomet, Vania, Giacometti, Andrea, Gianstefani, Alice, Giordani, Maria, Giorgini, Alessia, Grieco, Antonio, Guerra, Michele, Gulminetti, Roberto, Ieluzzi, Donatella, Imparato, Michele, Iodice, Valentina, La Monica, Silvia, Lazzarin, Adriano, Lenzi, Marco, Levrero, Massimo, Lichtner, Myriam, Lionetti, Raffaella, Guercio, Carmela Lo, Madonna, Salvatore, Magnani, Silvia, Maida, Ivana, Marignani, Massimo, Marrone, Aldo, Marsetti, Fabio, Martini, Silvia, Masarone, Mario, Maserati, Renato, Mastroianni, Claudio Maria, Memoli, Massimo, Menzaghi, Barbara, Merli, Manuela, Miele, Luca, Milella, Michele, Mondelli, Mario, Montalbano, Marzia, Monti, Monica, Morelli, Olivia, Morisco, Filomena, Nardone, Gaetano, Novara, Sergio, Onnelli, Giovanna, Onofrio, Mirella, Paganin, Simona, Pani, Luca, Parisi, Maria Rita, Parruti, Giustino, Pasquazzi, Caterina, Pasulo, Luisa, Perno, Carlo Federico, Persico, Marcello, Piai, Guido, Picciotto, Antonino, Pigozzi, Grazielle Marie, Piovesan, Sara, Piras, Maria Chiara, Pirisi, Massimo, Piscaglia, Anna Maria, Ponti, Laura, Potenza, Domenico, Pravadelli, Cecilia, Quartini, Mariano, Quirino, Tiziana, Raimondo, Giovanni, Rapaccini, Gian Ludovico, Rendina, Maria, Rizzardini, Giuliano, Rizzetto, Mario, Rizzo, Salvatore, Romagnoli, Dante, Romano, Antonietta, Rossi, Cristina, Rumi, Maria Grazia, Russello, Maurizio, Russo, Francesca Paolo, Russo, Maria Luisa, Sansonno, Domenico Ettore, Santantonio, Teresa Antonia, Saracco, Giorgio, Schimizzi, Anna Maria, Serviddio, Gaetano, Simeone, Filomena, Solinas, Attilio, Soria, Alessandro, Tabone, Marco, Taliani, Gloria, Tarantino, Giuseppe, Tarquini, Pierluigi, Tavio, Marcello, Termite, Antonio, Teti, Elisabetta, Toniutto, Pierluigi, Torti, Carlo, Tundi, Paolo, Vecchiet, Giacomo, Verucchi, Gabriella, Gentilucci, Umberto Vespasiani, Vinci, Maria, Vullo, Vincenzo, Zolfino, Teresa, Zuin, Massimo, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Cauda, Roberto (ORCID:0000-0002-1498-4229), de Luca, Andrea (ORCID:0000-0002-8311-6935), Grieco, Antonio (ORCID:0000-0002-0544-8993), Miele, Luca (ORCID:0000-0003-3464-0068), Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X), Ascione, Antonio, De Luca, Massimo, Melazzini, Mario, Montilla, Simona, Trotta, Maria Paola, Petta, Salvatore, Puoti, Massimo, Sangiovanni, Vincenzo, Messina, Vincenzo, Bruno, Savino, Izzi, Antonio, Villa, Erica, Aghemo, Alessio, Zignego, Anna Linda, Orlandini, Alessandra, Fontanella, Luca, Gasbarrini, Antonio, Marzioni, Marco, Giannini, Edoardo G., Craxì, Antonio, Abbati, Giuseppe, Alberti, Alfredo, Andreone, Pietro, Andreoni, Massimo, Angeli, Paolo, Angelico, Mario, Angarano, Gioacchino, Angrisani, Debora, Antinori, Andrea, Antonini, Cinzia, Avancini, Ivo, Barone, Michele, Bruno, Raffaele, Benedetti, Antonio, Bernabucci, Veronica, Blanc, Pier, Boarini, Chiara, Boffa, Nicola, Boglione, Lucio, Borghi, Vanni, Borgia, Guglielmo, Brancaccio, Giuseppina, Brunetto, Maurizia, Cacciola, Irene, Calabrese, Paolo, Calvaruso, Vincenza, Campagnolo, Davide, Canovari, Benedetta, Caporaso, Nicola, Capra, Franco, Carolo, Giada, Cassola, Giovanni, Castelli, Francesco, Cauda, Roberto, Silberstein, Francesca Ceccherini, Cecere, Roberto, Chessa, Luchino, Chiodera, Alessandro, Chirianni, Antonio, Ciancio, Alessia, Cima, Serena, Coco, Barbara, Colombo, Massimo, Coppola, Nicola, Corti, Giampaolo, Cosco, Lucio, Corradori, Silvia, Cozzolongo, Raffaele, Cristaudo, Antonio, Danieli, Elena, Monforte, Antonella D’Arminio, Monache, Marco delle, Del Poggio, Paolo, de Luca, Andrea, Dentone, Chiara, Di Biagio, Antonio, Di Leo, Alfredo, Di Perri, Giovanni, Di Stefano, Marco, D’Offizi, Giampiero, Donato, Francesca, Durante, Emanuele, Erne, Elke, Fagiuoli, Stefano, Falasca, Katia, Federico, Alessandro, Felder, Martina, Ferrari, Carlo, Gaeta, Giovanni Battista, Ganga, Roberto, Gatti, Pietro, Giacomet, Vania, Giacometti, Andrea, Gianstefani, Alice, Giordani, Maria, Giorgini, Alessia, Grieco, Antonio, Guerra, Michele, Gulminetti, Roberto, Ieluzzi, Donatella, Imparato, Michele, Iodice, Valentina, La Monica, Silvia, Lazzarin, Adriano, Lenzi, Marco, Levrero, Massimo, Lichtner, Myriam, Lionetti, Raffaella, Guercio, Carmela Lo, Madonna, Salvatore, Magnani, Silvia, Maida, Ivana, Marignani, Massimo, Marrone, Aldo, Marsetti, Fabio, Martini, Silvia, Masarone, Mario, Maserati, Renato, Mastroianni, Claudio Maria, Memoli, Massimo, Menzaghi, Barbara, Merli, Manuela, Miele, Luca, Milella, Michele, Mondelli, Mario, Montalbano, Marzia, Monti, Monica, Morelli, Olivia, Morisco, Filomena, Nardone, Gaetano, Novara, Sergio, Onnelli, Giovanna, Onofrio, Mirella, Paganin, Simona, Pani, Luca, Parisi, Maria Rita, Parruti, Giustino, Pasquazzi, Caterina, Pasulo, Luisa, Perno, Carlo Federico, Persico, Marcello, Piai, Guido, Picciotto, Antonino, Pigozzi, Grazielle Marie, Piovesan, Sara, Piras, Maria Chiara, Pirisi, Massimo, Piscaglia, Anna Maria, Ponti, Laura, Potenza, Domenico, Pravadelli, Cecilia, Quartini, Mariano, Quirino, Tiziana, Raimondo, Giovanni, Rapaccini, Gian Ludovico, Rendina, Maria, Rizzardini, Giuliano, Rizzetto, Mario, Rizzo, Salvatore, Romagnoli, Dante, Romano, Antonietta, Rossi, Cristina, Rumi, Maria Grazia, Russello, Maurizio, Russo, Francesca Paolo, Russo, Maria Luisa, Sansonno, Domenico Ettore, Santantonio, Teresa Antonia, Saracco, Giorgio, Schimizzi, Anna Maria, Serviddio, Gaetano, Simeone, Filomena, Solinas, Attilio, Soria, Alessandro, Tabone, Marco, Taliani, Gloria, Tarantino, Giuseppe, Tarquini, Pierluigi, Tavio, Marcello, Termite, Antonio, Teti, Elisabetta, Toniutto, Pierluigi, Torti, Carlo, Tundi, Paolo, Vecchiet, Giacomo, Verucchi, Gabriella, Gentilucci, Umberto Vespasiani, Vinci, Maria, Vullo, Vincenzo, Zolfino, Teresa, Zuin, Massimo, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Cauda, Roberto (ORCID:0000-0002-1498-4229), de Luca, Andrea (ORCID:0000-0002-8311-6935), Grieco, Antonio (ORCID:0000-0002-0544-8993), Miele, Luca (ORCID:0000-0003-3464-0068), and Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X)

Abstract

Purpose: To analyse safety and efficacy of treatment based on ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in the sub-group of GT1 patients older than 65 years. Methods: We collected data extracted from the ABACUS compassionate-use nationwide Italian programme, in patients with cirrhosis due to hepatitis C virus (HCV) Genotype-1 (GT1) or 4 and at high risk of decompensation. GT1-HCV-infected patients received once-daily ombitasvir/paritaprevir, with the pharmacokinetic enhancer ritonavir (25/150/100 mg) and twice-daily dasabuvir (250 mg) plus Ribavirin (RBV) (OBV/PTV/r + DSV + RBV) for 12 (GT1b) or 24 (GT1a) weeks. Endpoints were to evaluate safety and efficacy, the latter defined as HCV RNA negative 12 weeks after the end of treatment (SVR12). Results: Patients who suffered any adverse event (AE) were 74/240 (30.8%); 13/240 (5.4%) discontinued the treatment. A multivariate analysis found albumin < 3.5 g/dL (OR 2.04: 95% CI 1.0–4.2, p < 0.05) and hypertension (OR 4.6: 95% CI 2.3–9.2, p < 0.001) as variables independently associated with AE occurrence. The SVR12 was 95% (228/240). Multivariate analysis identified baseline bilirubin < 2 mg/dL (OR 4.9: 95% CI 1.17–20.71, p = 0.029) as the only variable independently associated with SVR12. Conclusion: Our findings suggest that OBV/PTV/r + DSV + RBV is safe and effective in real-life use in patients with compensated cirrhosis, HCV-GT1 infection, and age over 65.

Published
2018

225. PNPLA3 rs738409 polymorphism predicts development and severity of hepatic steatosis but not metabolic syndrome in celiac disease

Author

Tortora, Raffaella, Rispo, Antonio, Alisi, Anna, Imperatore, Nicola, Crudele, Annalisa, Ferretti, Francesca, Nobili, Valerio, Miele, Luca, Gerbino, Nicolò, Caporaso, Nicola, Morisco, Filomena, Miele, Luca (ORCID:0000-0003-3464-0068), Tortora, Raffaella, Rispo, Antonio, Alisi, Anna, Imperatore, Nicola, Crudele, Annalisa, Ferretti, Francesca, Nobili, Valerio, Miele, Luca, Gerbino, Nicolò, Caporaso, Nicola, Morisco, Filomena, and Miele, Luca (ORCID:0000-0003-3464-0068)

Abstract

Metabolic syndrome (MS) and hepatic steatosis (HS) have been described in patients with celiac disease (CD) after starting a gluten-free diet (GFD), but data on predictive factors for these conditions are scarce. Recently, the patatin-like phospholipase domain-containing protein 3 (PNPLA3) rs738409 has been identified as a key factor for HS development in the general population. The aim of the study was to evaluate the role of PNPLA3 rs738409 in the development of MS and HS in CD patients after starting GFD. Between June 2014 and September 2016, we consecutively enrolled CD patients with HS, while those without steatosis served as a control group. All patients underwent anthropometric and serologic investigations, ultrasonography (US) to assess the degree and severity of HS, and genotyping of the PNPLA3 rs738409 polymorphism. Finally, 370 subjects were enrolled (136 with and 234 without HS). At genotyping assays, the CC genotype was found in 194 subjects (52.4%), the CG genotype in 138 subjects (37.3%), and the GG genotype in 38 subjects (10.2%). At binary logistic regression, only CG and GG alleles were predictive for the development of HS (odds ratio (OR) 1.97; p < 0.01 for CG and OR 6.9; p < 0.001 for GG). Body mass index (BMI) (OR 3.8; p < 0.001) and waist circumference (OR 2.8; p = 0.03) at CD diagnosis were the only independent factors for the development of MS. Intergroup comparisons showed that the severe grade of HS was more frequently observed in GG than in CC carriers (74% vs. 11.3%, p < 0.001, OR 21.8). PNPLA3 CG and GG carriers with CD have a higher susceptibility to hepatic steatosis, but not to metabolic syndrome. Moreover, patients with GG alleles display more severe forms of HS based on ultrasound.

Published
2018

226. Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study

Author

Vitale, Alessandro, Farinati, Fabio, Noaro, Giulia, Burra, Patrizia, Pawlik, Timothy M., Bucci, Laura, Giannini, Edoardo G., Faggiano, Chiara, Ciccarese, Francesca, Rapaccini, Gian Lodovico, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Sacco, Rodolfo, Cabibbo, Giuseppe, Virdone, Roberto, Marra, Fabio, Felder, Martina, Morisco, Filomena, Benvegnù, Luisa, Gasbarrini, Antonio, Svegliati-Baroni, Gianluca, Foschi, Francesco Giuseppe, Olivani, Andrea, Masotto, Alberto, Nardone, Gerardo, Colecchia, Antonio, Fornari, Fabio, Marignani, Massimo, Vicari, Susanna, Bortolini, Emanuela, Cozzolongo, Raffaele, Grasso, Alessandro Giovanni, Aliberti, Camillo, Bernardi, Mauro, Frigo, Anna Chiara, Borzio, Mauro, Trevisani, Franco, Cillo, Umberto, Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Vitale, Alessandro, Farinati, Fabio, Noaro, Giulia, Burra, Patrizia, Pawlik, Timothy M., Bucci, Laura, Giannini, Edoardo G., Faggiano, Chiara, Ciccarese, Francesca, Rapaccini, Gian Lodovico, Di Marco, Maria, Caturelli, Eugenio, Zoli, Marco, Borzio, Franco, Sacco, Rodolfo, Cabibbo, Giuseppe, Virdone, Roberto, Marra, Fabio, Felder, Martina, Morisco, Filomena, Benvegnù, Luisa, Gasbarrini, Antonio, Svegliati-Baroni, Gianluca, Foschi, Francesco Giuseppe, Olivani, Andrea, Masotto, Alberto, Nardone, Gerardo, Colecchia, Antonio, Fornari, Fabio, Marignani, Massimo, Vicari, Susanna, Bortolini, Emanuela, Cozzolongo, Raffaele, Grasso, Alessandro Giovanni, Aliberti, Camillo, Bernardi, Mauro, Frigo, Anna Chiara, Borzio, Mauro, Trevisani, Franco, Cillo, Umberto, and Gasbarrini, Antonio (ORCID:0000-0002-7278-4823)

Abstract

Prognostic assessment of patients with hepatocellular carcinoma (HCC) at the time of diagnosis remains controversial and becomes even more complex at the time of restaging when new variables need to be considered. The aim of the current study was to evaluate the prognostic utility of restaging patients before proceeding with additional therapies for HCC. Two independent Italian prospective databases were used to identify 1,196 (training cohort) and 648 (validation cohort) consecutive patients with HCC treated over the same study period (2008-2015) who had complete restaging before decisions about additional therapies. The performance of the Italian Liver Cancer (ITA.LI.CA) prognostic score at restaging was compared with that of the Barcelona Clinic Liver Cancer, Hong Kong Liver Cancer, and Cancer of the Liver Italian Program systems. A multivariable Cox survival analysis was performed to identify baseline, restaging, or dynamic variables that were able to improve the predictive performance of the prognostic systems. At restaging, 35.3% of patients maintained stable disease; most patients were either down-staged by treatment (27.2%) or had disease progression (37.5%). The ITA.LI.CA scoring system at restaging demonstrated the best prognostic performance in both the training and validation cohorts (c-index 0.707 and 0.722, respectively) among all systems examined. On multivariable analysis, several variables improved the prognostic ability of the ITA.LI.CA score at restaging, including progressive disease after the first treatment, Model for End-Stage Liver Disease at restaging, and choice of nonsurgical treatment as additional therapy. A new ITA.LI.CA restaging model was created that demonstrated high discriminative power in both the training and validation cohorts (c-index 0.753 and 0.745, respectively). Conclusion: Although the ITA.LI.CA score demonstrated the best prognostic performance at restaging, other variables should be considered to improve the prognostic a

Published
2018

227. Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice

Author

Giannini, Edoardo G, Bucci, Laura, Garuti, Francesca, Brunacci, Matteo, Lenzi, Barbara, Valente, Matteo, Caturelli, Eugenio, Cabibbo, Giuseppe, Piscaglia, Fabio, Virdone, Roberto, Felder, Martina, Ciccarese, Francesca, Foschi, Francesco Giuseppe, Sacco, Rodolfo, Baroni, Gianluca Svegliati, Farinati, Fabio, Rapaccini, Gian Ludovico, Olivani, Andrea, Gasbarrini, Antonio, Di Marco, Maria, Morisco, Filomena, Zoli, Marco, Masotto, Alberto, Borzio, Franco, Benvegnù, Luisa, Marra, Fabio, Colecchia, Antonio, Nardone, Gerardo, Bernardi, Mauro, Trevisani, Franco, Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X), Gasbarrini, Antonio (ORCID:0000-0002-7278-4823), Giannini, Edoardo G, Bucci, Laura, Garuti, Francesca, Brunacci, Matteo, Lenzi, Barbara, Valente, Matteo, Caturelli, Eugenio, Cabibbo, Giuseppe, Piscaglia, Fabio, Virdone, Roberto, Felder, Martina, Ciccarese, Francesca, Foschi, Francesco Giuseppe, Sacco, Rodolfo, Baroni, Gianluca Svegliati, Farinati, Fabio, Rapaccini, Gian Ludovico, Olivani, Andrea, Gasbarrini, Antonio, Di Marco, Maria, Morisco, Filomena, Zoli, Marco, Masotto, Alberto, Borzio, Franco, Benvegnù, Luisa, Marra, Fabio, Colecchia, Antonio, Nardone, Gerardo, Bernardi, Mauro, Trevisani, Franco, Rapaccini, Gian Ludovico (ORCID:0000-0002-6467-857X), and Gasbarrini, Antonio (ORCID:0000-0002-7278-4823)

Abstract

N/A

Published
2018

228. SAT171 - Long-term albumin administration is not futile in patients with cirrhosis and uncomplicated ascites not normalizing serum albumin concentration with treatment

Author

Tufoni, Manuel, Caraceni, Paolo, Zaccherini, Giacomo, Riggio, Oliviero, Angeli, Paolo, Alessandria, Carlo, Neri, Sergio, Foschi, Francesco Giuseppe, Levantesi, Fabio, Airoldi, Aldo, Simone, Loredana, Svegiati-Baroni, Gianluca, Fagiuoli, Stefano, Laffi, Giacomo, Cozzolongo, Raffaele, Di Marco, Vito, Sangiovanni, Vincenzo, Morisco, Filomena, Toniutto, Pierluigi, Tortora, Annalisa, De Marco, Rosanna, Nardelli, Silvia, Piano, Salvatore, Elia, Chiara, Roncadori, Andrea, Baldassarre, Maurizio, and Bernardi, Mauro

Published
2020
Full Text
View/download PDF

229. THU145 - Effective albumin concentration and albumin function improve after long-term albumin treatment in patients with decompensated cirrhosis

Author

Baldassarre, Maurizio, Tufoni, Manuel, Zaccherini, Giacomo, Campion, Daniela, Foschi, Francesco Giuseppe, Nardelli, Silvia, Morisco, Filomena, Federico, Alessandro, Massironi, Sara, Airoldi, Aldo, Vizzutti, Francesco, Antognoli, Agnese, Gagliardi, Martina, Donadei, Chiara, Waterstradt, Katja, Naldi, Marina, Bernardi, Mauro, and Caraceni, Paolo

Published
2020
Full Text
View/download PDF

231. Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV

Author

Karampatou, Aimilia, primary, Han, Xue, additional, Kondili, Loreta A., additional, Taliani, Gloria, additional, Ciancio, Alessia, additional, Morisco, Filomena, additional, Critelli, Rosina Maria, additional, Baraldi, Enrica, additional, Bernabucci, Veronica, additional, Troshina, Giulia, additional, Guarino, Maria, additional, Tagliavini, Simonetta, additional, D'Ambrosio, Federica, additional, Bristot, Laura, additional, Turco, Laura, additional, Rosato, Stefano, additional, Vella, Stefano, additional, Trenti, Tommaso, additional, Neri, Isabella, additional, La Marca, Antonio, additional, Manthena, Shivaji, additional, Goldstein, Andrea S., additional, Bruno, Savino, additional, Bao, Yanjun, additional, Gonzalez, Yuri Sanchez, additional, Villa, Erica, additional, Craxì, A., additional, Petta, S., additional, Calvaruso, V., additional, Brunetto, M., additional, Coco, B., additional, Chessa, L., additional, Pasetto, M.C., additional, Bigliotti, E., additional, Tamburrini, F., additional, Montalto, G., additional, Capitano, A.R., additional, Ieluzzi, D., additional, Fattovich, G., additional, Zignego, A.L., additional, Monti, M., additional, Gragnani, L., additional, Zuin, M., additional, Finati, E., additional, Giorgini, A., additional, Angarano, G., additional, Milella, M., additional, Alessandro, F., additional, Dallio, M., additional, Mazzella, G., additional, Lazzarini, G., additional, Di Fine, M., additional, Russo, F.P., additional, Zanetto, A., additional, Castelli, F., additional, Zaltron, S., additional, Raimondo, G., additional, Filomia, R., additional, Puoti, M., additional, Danieli, E., additional, Strazzabosco, M., additional, Gemma, M., additional, Angelico, M., additional, De Leonardis, F., additional, Gori, A., additional, Cappelletti, E., additional, Bruno, R., additional, Cima, S., additional, Coppola, C., additional, Amoruso, D.C., additional, Andreone, P., additional, Simonetti, G., additional, Gaeta, G.B., additional, Brancaccio, G., additional, Toniutto, P., additional, Dissegna, D., additional, Mondelli, M., additional, Ludovisi, S., additional, Persico, M., additional, Masarone, M., additional, Torti, C., additional, Strazzulla, A., additional, Rosina, F., additional, Framarin, L., additional, Weimer, L.E., additional, Quaranta, M.G., additional, Falzano, L., additional, and Mallano, A., additional

Published
2018
Full Text
View/download PDF

232. No differences of response to telaprevir based therapy in cirrhotic and non cirrhotic patients with RVR: a real life data from South Italy. Hepatology 2014; 60 (S1): 695A-696A. Abstract. 1018

Author

Persico, M, Masarone, M, Rosato, V, Di Costanzo, Gg, Coppola, C, Coppola, N, Megna, As, Gentile, Ivan, De Luna, A, Federico, A, Precone, Df, Claar, E, CAMERA, SILVIA, GRANATA, ROCCO, MORISCO, FILOMENA, Persico, M, Masarone, M, Camera, Silvia, Rosato, V, Granata, Rocco, Di Costanzo, Gg, Coppola, C, Coppola, N, Megna, A, Gentile, Ivan, De Luna, A, Federico, A, Precone, Df, Claar, E, and Morisco, Filomena

Published
2014

233. No differences of response to telaprevir based therapy in cirrhotic and non cirrhotic patients with RVR: Real life data from South Italy

Author

GENTILE, Ivan, Persico M, Masarone M, Camera S, Rosato V., Granata G, Di Costanzo G, Coppola C, Coppola N, Salomone Megna A, De Luna A, Federico A, Precone D, Claar E, MORISCO, FILOMENA, Persico, M, Masarone, M, Camera, S, Rosato, V, Granata, R, Di Costanzo, Gg, Coppola, C, Coppola, Nicola, Salomone Megna, A, Gentile, I, De Luna, A, Federico, Alessandro, Precone, D, Claar, E, Morisco, F., Gentile, Ivan, Rosato, V., Granata, G, Di Costanzo, G, Coppola, N, Federico, A, and Morisco, Filomena

Published
2014

234. Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients

Author

Costa L, Caso F, Atteno M, Giannitti C, Spadaro A, Ramonda R, Vezz? M, Fiocco U, Galeazzi M, Punzi L, SCARPA, RAFFAELE, COSTA, LUISA, DEL PUENTE, ANTONIO, MORISCO, FILOMENA, Costa, L, Caso, F, Atteno, M, Giannitti, C, Spadaro, A, Ramonda, R, Vezz?, M, DEL PUENTE, Antonio, Morisco, Filomena, Fiocco, U, Galeazzi, M, Punzi, L, Scarpa, Raffaele, Costa, Luisa, Caso, Francesco, Atteno, Mariangela, Giannitti, Chiara, Spadaro, Antonio, Ramonda, Roberta, Vezzù, Maristella, Del Puente, Antonio, Fiocco, Ugo, Galeazzi, Mauro, and Punzi, Leonardo

Subjects
Male, Time Factors, Inflammatory arthritis, Arthritis, medicine.disease_cause, Gastroenterology, Receptors, Tumor Necrosis Factor, Etanercept, Retrospective Studie, Antirheumatic Agent, Anti-TNF-α, Alanine Transaminase, General Medicine, Middle Aged, Viral Load, Hepatitis C, HCV infection, Antirheumatic Agents, Biological Product, Female, Viral load, Human, medicine.drug, medicine.medical_specialty, Time Factor, Hepatitis C virus, Antibodies, Monoclonal, Humanized, Psoriatic arthritis, Rheumatology, Internal medicine, medicine, Adalimumab, Humans, Aspartate Aminotransferases, Aged, Retrospective Studies, Inflammation, Biological Products, Tumor Necrosis Factor-alpha, business.industry, Psoriatic arthriti, Arthritis, Psoriatic, Aspartate Aminotransferase, medicine.disease, Immunoglobulin G, Concomitant, Immunology, business
Abstract

Psoriatic arthritis (PsA) is an inflammatory arthropathy associated with skin and/or nail psoriasis. TNF-α, in addition to its pro-inflammatory role, is an essential cytokine for the host's defense, and its depletion by treatment may facilitate the risk of viral infections or their reactivation. The aim of this study was to evaluate the efficacy and safety of TNF-α blockers in PsA patients with concurrent hepatitis C virus (HCV) infection. This is a multicenter study carried out in four Italian centers specialized in the diagnosis and treatment of PsA. At baseline and after 6 (T6) and 12 months (T12) of therapy, data concerning PsA activity and liver tests were registered. A total of 15 PsA patients with concomitant HCV infection were included in the study. At baseline, 13 patients had low viral load, and liver enzyme tests were within the normal range. During the observation period, these values remained stable. On the other hand, at baseline, a high viral load with slightly increased values of AST and ALT was detected in one patient. At T6 and T12, these values decreased. The remaining patient, at baseline, had low viral load, but with slightly increased AST and ALT values that normalized during the observation period. This is the greatest sample size available in the literature on this topic. The data suggests that anti-TNF-α agents are effective and safe in PsA patients with concomitant HCV. We suggest that the use of anti-TNF-α agents, accompanied by close monitoring, could be a therapeutic option.

Published
2014

235. Hepatitis C virus infection in end stage renal disease and after kidney transplant

Author

Rodriguez Castro, Kryssia Isabel, Rigotti, Paolo, Rugge, Massimo, Burra, Patrizia, MORISCO, FILOMENA, Rodriguez Castro, Kryssia Isabel, Morisco, Filomena, Rigotti, Paolo, Rugge, Massimo, and Burra, Patrizia

Subjects
Antiviral Agent, Hepaciviru, Time Factors, Time Factor, Genotype, Hepacivirus, Viral Load, Antiviral Agents, Hepatitis C, Kidney Transplantation, Immunosuppressive Agent, Prospective Studie, Treatment Outcome, Renal Dialysi, Recurrence, Renal Dialysis, Biological Marker, Humans, Kidney Failure, Chronic, RNA, Viral, Virus Activation, Prospective Studies, Biomarkers, Immunosuppressive Agents, Human
Published
2014

236. Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use

Author

Giannini EG, Sammito G, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Svegliati Baroni G, Virdone R, Trevisani F, Italian Liver Cancer Group, MORISCO, FILOMENA, Giannini, Eg, Sammito, G, Farinati, F, Ciccarese, F, Pecorelli, A, Rapaccini, Gl, Di Marco, M, Caturelli, E, Zoli, M, Borzio, F, Cabibbo, G, Felder, M, Gasbarrini, A, Sacco, R, Foschi, Fg, Missale, G, Morisco, Filomena, Svegliati Baroni, G, Virdone, R, Trevisani, F, and Italian Liver Cancer, Group

Published
2014

238. Hepatitis C Virus Clearance in Older Adults

Author

Ippolito, Antonio Massimo, primary, Iacobellis, Angelo, additional, Milella, Michele, additional, Conti, Fabio, additional, Messina, Vincenzo, additional, Valvano, Maria Rosa, additional, Niro, Grazia Anna, additional, Morisco, Filomena, additional, Barone, Michele, additional, Termite, Antonio Patrizio, additional, Brancaccio, Giuseppina, additional, and Andriulli, Angelo, additional

Published
2017
Full Text
View/download PDF

240. Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network

Author

Kondili, Loreta A., primary, Gaeta, Giovanni Battista, additional, Brunetto, Maurizia Rossana, additional, Di Leo, Alfredo, additional, Iannone, Andrea, additional, Santantonio, Teresa Antonia, additional, Giammario, Adele, additional, Raimondo, Giovanni, additional, Filomia, Roberto, additional, Coppola, Carmine, additional, Amoruso, Daniela Caterina, additional, Blanc, Pierluigi, additional, Del Pin, Barbara, additional, Chemello, Liliana, additional, Cavalletto, Luisa, additional, Morisco, Filomena, additional, Donnarumma, Laura, additional, Rumi, Maria Grazia, additional, Gasbarrini, Antonio, additional, Siciliano, Massimo, additional, Massari, Marco, additional, Corsini, Romina, additional, Coco, Barbara, additional, Madonia, Salvatore, additional, Cannizzaro, Marco, additional, Zignego, Anna Linda, additional, Monti, Monica, additional, Russo, Francesco Paolo, additional, Zanetto, Alberto, additional, Persico, Marcello, additional, Masarone, Mario, additional, Villa, Erica, additional, Bernabucci, Veronica, additional, Taliani, Gloria, additional, Biliotti, Elisa, additional, Chessa, Luchino, additional, Pasetto, Maria Cristina, additional, Andreone, Pietro, additional, Margotti, Marzia, additional, Brancaccio, Giuseppina, additional, Ieluzzi, Donatella, additional, Borgia, Guglielmo, additional, Zappulo, Emanuela, additional, Calvaruso, Vincenza, additional, Petta, Salvatore, additional, Falzano, Loredana, additional, Quaranta, Maria Giovanna, additional, Weimer, Liliana Elena, additional, Rosato, Stefano, additional, Vella, Stefano, additional, and Giannini, Edoardo Giovanni, additional

Published
2017
Full Text
View/download PDF

244. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study

Author

Petta, Salvatore, primary, Marzioni, Marco, additional, Russo, Pierluigi, additional, Aghemo, Alessio, additional, Alberti, Alfredo, additional, Ascione, Antonio, additional, Antinori, Andrea, additional, Bruno, Raffaele, additional, Bruno, Savino, additional, Chirianni, Antonio, additional, Gaeta, Giovanni Battista, additional, Giannini, Edoardo G, additional, Merli, Manuela, additional, Messina, Vincenzo, additional, Montilla, Simona, additional, Perno, Carlo Federico, additional, Puoti, Massimo, additional, Raimondo, Giovanni, additional, Rendina, Maria, additional, Silberstein, Francesca Ceccherini, additional, Villa, Erica, additional, Zignego, Anna Linda, additional, Pani, Luca, additional, Craxì, Antonio, additional, Tabone, Marco, additional, Andreoni, Massimo, additional, Teti, Elisabetta, additional, Angelico, Mario, additional, Persico, Marcello, additional, Masarone, Mario, additional, Chiodera, Aledssandro, additional, Solinas, Attilio, additional, delle Monache, Marco, additional, Cecere, Roberto, additional, Maria Schimizzi, Anna, additional, Piovesan, Sara, additional, Campagnolo, Davide, additional, Chiara Piras, Maria, additional, Zolfino, Teresa, additional, Paolo Russo, Francesca, additional, Morelli, Olivia, additional, Sangiovanni, Vincenzo, additional, Onofrio, Mirella, additional, Iodice, Valentina, additional, Izzi, Antonio, additional, Pirisi, Massimo, additional, Danieli, Elena, additional, Vinci, Maria, additional, Rizzardini, Giuliano, additional, Fagiuoli, Stefano, additional, Pasulo, Luisa, additional, D'Arminio Monforte, Antonella, additional, Zuin, Massimo, additional, Giorgini, Alessia, additional, Simeone, Filomena, additional, Piali, Guido, additional, Lo Guercio, Carmela, additional, Federico, Alessandro, additional, Brancaccio, Giuseppina, additional, Marrone, Aldo, additional, Abbati, Giuseppe, additional, Boarini, Chiara, additional, Borghi, Vanni, additional, Bernabucci, Veronica, additional, Corti, Giampaolo, additional, Monti, Monica, additional, Rizzetto, Mario, additional, Martini, Silvia, additional, Andreone, Pietro, additional, Gianstefani, Alice, additional, Lenzi, Marco, additional, Verucchi, Gabriella, additional, Toniutto, Pierluigi, additional, Borgia, Guglielmo, additional, Caporaso, Nicola, additional, Morisco, Filomena, additional, Nardone, Gaetano, additional, Angrisani, Debora, additional, Giacometti, Andrea, additional, Benedetti, Antonio, additional, Tarantino, Giuseppe, additional, Marsetti, Fabio, additional, Tavio, Marcello, additional, Novara, Sergio, additional, Antonia Santantonio, Teresa, additional, Serviddio, Gaetano, additional, Brunetto, Maurizia, additional, Coco, Barbara, additional, Angarano, Gioacchino, additional, Milella, Michele, additional, Barone, Michele, additional, Di Leo, Alfredo, additional, Ettore Sansonno, Domenico, additional, Cacciola, Irene, additional, Boffa, Nicola, additional, Saracco, Giorgio, additional, Di Biagio, Antonio, additional, Picciotto, Antonino, additional, de Luca, Andrea, additional, Calvaruso, Vincenza, additional, Corradori, Silvia, additional, Ferrari, Carlo, additional, Orlandini, Alessandra, additional, Maida, Ivana, additional, Torti, Carlo, additional, Chessa, Luchino, additional, Felder, Martina, additional, Vespasiani Gentilucci, Umberto, additional, Angeli, Paolo, additional, Romano, Antonietta, additional, Ludovico Rapaccini, Gian, additional, Miele, Luca, additional, Cima, Serena, additional, Luisa Russo, Maria, additional, Cozzolongo, Raffaele, additional, Onnelli, Giovanna, additional, D'Offizi, Giampiero, additional, Lionetti, Raffaella, additional, Montalbano, Marzia, additional, Guerra, Michele, additional, Di Perri, Giovanni, additional, Boglione, Lucio, additional, Capra, Franco, additional, Carolo, Giada, additional, Ieluzzi, Donatella, additional, Antonini, Cinzia, additional, Termite, Antonio, additional, Madonia, Salvatore, additional, Tarquini, Pierluigi, additional, Parruti, Giustino, additional, Vecchiet, Giacomo, additional, Falasca, Katia, additional, Menzaghi, Barbara, additional, Quirino, Tiziana, additional, Dentone, Chiara, additional, Maria Piscaglia, Anna, additional, Rossi, Cristina, additional, Giordani, Maria, additional, Fontanella, Luca, additional, Cassola, Giovanni, additional, Russello, Maurizio, additional, Cristaudo, Antonio, additional, Giacomet, Vania, additional, Colombo, Massimo, additional, Donato, Francesca, additional, Durante, Emanuele, additional, Cosco, Lucio, additional, Marignani, Massimo, additional, Quartini, Mariano, additional, Memoli, Massimo, additional, Ganga, Roberto, additional, Ponti, Laura, additional, Soria, Alessandro, additional, Grazia Rumi, Maria, additional, Gulminetti, Roberto, additional, Maserati, Renato, additional, Mondelli, Mario, additional, Lazzarin, Adriano, additional, Rita Parisi, Maria, additional, Canovari, Benedetta, additional, Avancini, Ivo, additional, Pravadelli, Cecilia, additional, Blanc, Pier, additional, Pasquazzi, Caterina, additional, Maria Mastroianni, Claudio, additional, Lichtner, Myriam, additional, Distefano, Marco, additional, Magnani, Silvia, additional, Paganin, Simona, additional, Erne, Elke, additional, Gatti, Pietro, additional, Tundi, Paolo, additional, Calabrese, Paolo, additional, Gasbarrini, Antonio, additional, Grieco, Antonio, additional, Coppola, Nicola, additional, Del Poggio, Paolo, additional, Levrero, Massimo, additional, Talliani, Gloria, additional, Vullo, Vincenzo, additional, Cauda, Roberto, additional, La Monica, Silvia, additional, Potenza, Domenico, additional, Rizzo, Salvatore, additional, Castelli, Francesco, additional, Marie Pigozzi, Grazielle, additional, Ciancio, Alessia, additional, Romagnoli, Dante, additional, Barchetti, Federica, additional, Ivanovic, Jelena, additional, Longo, Olimpia, additional, Petraglia, Sandra, additional, and Paola Trotta, Maria, additional

Published
2017
Full Text
View/download PDF

245. Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology

Author

Stroffolini, Tommaso, primary, Sagnelli, Evangelista, additional, Gaeta, Giovanni Battista, additional, Sagnelli, Caterina, additional, Andriulli, Angelo, additional, Brancaccio, Giuseppina, additional, Pirisi, Mario, additional, Colloredo, Guido, additional, Morisco, Filomena, additional, Furlan, Caterina, additional, Almasio, Piero Luigi, additional, Stroffolini, Tommaso, additional, Babudieri, Sergio, additional, Cacopardo, Bruno, additional, Coppola, Nicola, additional, De Luca, Massimo, additional, Licata, Anna, additional, Pisaturo, Mariantonietta, additional, Rosina, Floriano, additional, Russello, Maurizio, additional, Santantonio, Teresa, additional, and Smedile, Antonina, additional

Published
2017
Full Text
View/download PDF

246. Sustained Virological Response by Direct Antiviral Agents in HCV Leads to an Early and Significant Improvement of Liver Fibrosis

Author

Persico, Marcello, primary, Rosato, Valerio, additional, Aglitti, Andrea, additional, Precone, Davide, additional, Corrado, Mariano, additional, Luna, Antonio De, additional, Morisco, Filomena, additional, Camera, Silvia, additional, Federico, Alessandro, additional, Dallio, Marcello, additional, Claar, Ernesto, additional, Caporaso, Nicola, additional, and Masarone, Mario, additional

Published
2017
Full Text
View/download PDF

247. HepaDisk – A new quality of life questionnaire for HCV patients.

Author

Fagiuoli, Stefano, Caporaso, Nicola, Morisco, Filomena, Buelli, Fabio, Gualberti, Giuliana, Saragaglia, Valeria, Chessa, Luchino, Corti, Giampaolo, Maida, Ivana, Mastroianni, Claudio M., Pirisi, Mario, Russo, Francesco P., Farina, Francesca, Giannitrapani, Lydia, Toniutto, Pierluigi, Tarquini, Pierluigi, Tundo, Paolo, Vecchiet, Jacopo, Vinci, Maria, and Taliani, Gloria

Abstract

Since most patients with hepatitis C virus (HCV) infection now receive treatment irrespective of liver disease severity, special attention to patient quality of life (QoL), including psycho-social aspects, is required. No QoL questionnaire is specific for patients with HCV. To develop and validate a short Italian questionnaire (HepaDisk) assessing the QoL of patients affected by HCV with intuitive graphic results that is understandable by patients and physicians. A questionnaire, drafted by a steering committee, underwent a Delphi survey. A multicenter, observational study was conducted to validate the developed HepaDisk versus other tools (CLDQ-I, SF-36, WPAI:HCV), and to evaluate its correlation with disease severity in Italian patients with HCV. The 10-item questionnaire was validated in 214 patients. HepaDisk showed a high correlation with CLDQ overall score and WPAI:HCV activity impairment (Spearman's rank correlation: 0.651 and 0.595, respectively) and a lower correlation with SF-36. Strong internal consistency (Cronbach coefficient: 0.912), good test–retest reliability (Pearson's correlation coefficient: 0.789; 95% CI, 0.714–0.865), and responsiveness to changes among improved patients were demonstrated. HepaDisk is a reliable and user-friendly tool that can monitor disease impact on patient QoL over time, providing a visual representation easily understandable by both patients and physicians. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

248. A snapshot of virological presentation and outcome of immunosuppression‐driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection.

Author

Salpini, Romina, Battisti, Arianna, Colagrossi, Luna, Di Carlo, Domenico, Fabeni, Lavinia, Piermatteo, Lorenzo, Cerva, Carlotta, Lichtner, Miriam, Mastroianni, Claudio, Marignani, Massimo, Maylin, Sarah, Delaugerre, Constance, Morisco, Filomena, Coppola, Nicola, Marrone, Aldo, Angelico, Mario, Sarmati, Loredana, Andreoni, Massimo, Perno, Carlo‐Federico, and Ceccherini‐Silberstein, Francesca

Subjects
RITUXIMAB, LIVER failure, PHOTOGRAPHS, THERAPEUTICS, IMMUNOSUPPRESSIVE agents, TERMINALLY ill
Abstract

The study was undertaken in order to provide a snapshot from real clinical practice of virological presentation and outcome of patients developing immunosuppression‐driven HBV reactivation. Seventy patients with HBV reactivation were included (66.2% treated with rituximab, 10% with corticosteroids and 23.8% with other immunosuppressive drugs). Following HBV reactivation, patients received anti‐HBV treatment for a median (IQR) follow‐up of 31(13‐47) months. At baseline‐screening, 72.9% of patients were HBsAg‐negative and 27.1% HBsAg‐positive. About 71.4% had a diagnosis of biochemical reactivation [median (IQR) HBV DNA and ALT: 6.9 (5.4‐7.8) log IU/mL and 359 (102‐775) U/L]. Moreover, 10% of patients died from hepatic failure. Antiviral prophylaxis was documented in 57.9% and 15.7% of HBsAg‐positive and HBsAg‐negative patients at baseline‐screening (median [IQR] prophylaxis duration: 24[15‐33] and 25[17‐36] months, respectively). Notably, HBV reactivation occurred 2‐24 months after completing the recommended course of anti‐HBV prophylaxis in 35.3% of patients. By analysing treatment outcome, the cumulative probability of ALT normalization and of virological suppression was 97% and 69%, respectively. Nevertheless, in patients negative to HBsAg at baseline‐screening, only 27% returned to HBsAg‐negative status during prolonged follow‐up, suggesting the establishment of chronic infection. In conclusion, most patients received a diagnosis of HBV reactivation accompanied by high ALT and 10% died for hepatic failure, supporting the importance of strict monitoring for an early HBV reactivation diagnosis. Furthermore, HBV reactivation correlates with high risk of HBV chronicity in patients negative for HBsAg at baseline‐screening, converting a silent into a chronic infection, requiring long‐term antiviral treatment. Finally, a relevant proportion of patients experienced HBV reactivation after completing the recommended course of anti‐HBV prophylaxis, suggesting the need to reconsider proper duration of prophylaxis particularly in profound immunosuppression. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

249. The burden of HBV infection in HCV patients in Italy and the risk of reactivation under DAA therapy.

Author

Stroffolini, Tommaso, Sagnelli, Evangelista, Sagnelli, Caterina, Smedile, Antonina, Furlan, Caterina, Morisco, Filomena, Coppola, Nicola, Andriulli, Angelo, and Almasio, Piero Luigi

Abstract

Abstract Background There is increasing awareness of HBV reactivation in HCV-RNA-positive/HBV-coinfected patients with chronic liver disease (CLD) treated with oral direct-acting antivirals (DAAs). Aim To provide figures on the prevalence of HBV markers in HCV-RNA-positive subjects in Italy, where these findings are lacking. Methods All subjects aged ≥18 years with CLD consecutively referring to Italian liver units located throughout country were prospectively enrolled in two national surveys in 2001 and 2014. Results The total number of HCV-RNA-positive cases was 6984; 356 (5.1%) subjects vaccinated against HBV were excluded. A total of 6628 cases were evaluated. The prevalence rates of HBsAg, isolated anti-HBc and anti-HBc/anti-HBs-positivity were 2.9%, 8.1% and 14.7%, respectively. Among the estimated one million HCV-RNA-positive subjects in Italy, a substantial number of subjects are at risk of HBV reactivation due to DAA therapy. The prevalence of liver cirrhosis was higher than that of CLD in HBsAg-positive subjects (4.4% vs. 2.6%, p < 0.01) but not in those positive for other HBV markers. Conclusions These findings outline the burden of HBV markers among HCV-RNA-positive subjects in Italy, where in 2017 reimbursement for DAA therapy by the National Health System became universal for all patients with chronic HCV infection. HBV vaccination coverage should be greatly extended, since nearly two thirds of subjects in this study resulted negative for any HBV marker. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

250. Concomitant Interferon-alfa and chemotherapy in hepatitis C and colorectal cancer: a case report

Author

GENTILE, Ivan, DE STEFANO, ALFONSO, DI FLUMERI, GIUSY, BUONOMO, ANTONIO RICCARDO, CARLOMAGNO, Chiara, MORISCO, FILOMENA, DE PLACIDO, SABINO, BORGIA, GUGLIELMO, Gentile, Ivan, DE STEFANO, Alfonso, DI FLUMERI, Giusy, Buonomo, ANTONIO RICCARDO, Carlomagno, Chiara, Morisco, Filomena, DE PLACIDO, Sabino, and Borgia, Guglielmo

Subjects
adjuvant chemotherapy, acute hepatitis C, IFN-alfa, colorectal cancer
Abstract

Hepatitis C virus (HCV) infection is one of the main causes of liver disease worldwide. Patients undergoing surgery are at risk of acquiring acute HCV infection and those undergoing surgical eradication of a neoplasia may be indicated for adjuvant treatment. Therefore, unlike chronic infection, such patients may simultaneously need antiviral therapy with interferon for acute hepatitis C and cytotoxic chemotherapy. To date, no data are available regarding the efficacy and tolerability of concomitant interferon treatment and antineoplastic chemotherapy in the setting of acute hepatitis C treatment. Here, we report the case of a 60-yearold man who developed acute hepatitis C after left hemicolectomy for an adenocarcinoma. He received concomitant antiviral treatment with interferon-α and adjuvant chemotherapy with capecitabine and oxaliplatin. Both treatments were well tolerated and the patient completed the scheduled therapies. HCV infection was eradicated and the patient is free of neoplastic disease two years and 6 months after surgery.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results